Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.57 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17992755 | 1.00 | TAAR1 (0.57) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL11395950 | 0.84 | SLC6A4 (0.60) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL24287739 | 0.81 | TAAR1 (0.47) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL4785594 | 0.81 | SIGMAR1 (0.64) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL27210144 | 0.81 | TAAR1 (0.50) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL902381 | 0.81 | SIGMAR1 (0.50) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL22957765 | 0.81 | SIGMAR1 (0.52) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL11021208 | 0.81 | SIGMAR1 (0.54) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL21880070 | 0.80 | TAAR1 (0.54) | TAAR1SIGMAR1SLC18A2SLC6A2SLC6A4 | |
| SCHEMBL7969024 | 0.79 | CYP3A4 (0.42) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3569593-A1 | PRODUCTION OF AMINES VIA A HYDROAMINOMETHYLATION REACTION | Universität Wien (AT) | 2019-11-20 | — | — | EP | disclosed |
| EP-3569593-A1 | PRODUCTION OF AMINES VIA A HYDROAMINOMETHYLATION REACTION | Universität Wien (AT) | 2019-11-20 | — | — | EP | disclosed |
| EP-3327027-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | Pfizer Inc (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2884280-B1 | Method for evaluating the scent performance of perfumes and perfume mixtures | SYMRISE AG (DE) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018051107-A1 | FLUOROHYDROXYPROLINE DERIVATIVES USEFUL IN THE PREPARATION OF PROTEOLYSIS TARGETED CHIMERAS | UNIVERSITY OF DUNDEE (GB) | 2018-03-22 | — | — | WO | disclosed |
| US-9249186-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9138486-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| EP-0997474-B1 | Antithrombotic agents | PFIZER (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6271385-B1 | FUNGICIDES (SUCH AS THOSE FOR USE IN FARMING AND HORTICULTURE). | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-1020441-A1 | N-HETEROCYCLIC METHYLPROPYLAMINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND GERMICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | TAAR1 4230/4885SIGMAR1 3298/4885SLC18A2 2867/4885 |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | TAAR1 1793/4885SIGMAR1 2051/4885SLC18A2 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.